In this episode, hosts Anthony Davies and Michael Adeniya get to talk to two cell therapy CMC experts in Delfi Krishna, Director Cell and Gene Therapy Platform: R&D Strategy at GSK and Jacob Peterson, Corporate Vice President Head of Stem Cell R&D with Novo Nordisk.   The discussion tackled cellular analytics, manufacturing and the impact the Covid-19 pandemic is having on both capacity and clinical pipelines.   Delfi kicks us off with her company's challenge around managing the cost of goods for autologous therapies. A special thanks to Jacob for joining us from vacation! 😎   And here's the link to the European CDMO map! 🌍 http://bit.ly/ATEuropemanufacturing19   If you’re not already, don’t forget to sign-up as a Phacilitate member, it’s FREE! Every fortnight you’ll get the latest market intelligence, new ideas and exclusive event offers straight to your inbox.    Join a community with the same goal; to help advance a new standard in healthcare. https://www.phacilitate.co.uk/membership